Company intelligence / Profile preview

Unity

South San Francisco, California, USA

Ownership: Private
Development stage: Other

Overview

Unity Biotechnology is a clinical-stage biotech company developing senolytic small molecules to selectively eliminate senescent cells, aiming to treat age-related diseases. Its lead asset, UBX1325, has shown statistically significant and clinically meaningful improvement in vision in Phase 2a trials for diabetic macular edema, and is now in Phase 2b. The company previously halted development in osteoarthritis after clinical setbacks. As of late 2024, Unity remains pre-commercial, focused on advancing its ophthalmology pipeline and securing funding for late-stage development[1][3].

Therapeutic areas: OphthalmologyRheumatology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Unity.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Unity.

Explore the full profile